Perspective Therapeutics Receives Strong-Buy Upgrade from Lifesci Capital

Perspective Therapeutics (NYSE:CATX) has been upgraded to a "strong-buy" rating by analysts at Lifesci Capital, according to a research note released to investors on Thursday.

Various other financial institutions have recently provided their insights on CATX. For instance, on November 25th, Bank of America downgraded the stock from a "buy" rating to "neutral" and cut its price target from $24.00 to $5.00. Meanwhile, Wedbush confirmed an "outperform" rating with a target price of $11.00 for the shares in a report issued on January 24th. Oppenheimer also revised its price target down from $22.00 to $16.00 while maintaining an "outperform" rating on November 22nd. Additionally, Cantor Fitzgerald upgraded Perspective Therapeutics to a "strong-buy" just two days earlier. Royal Bank of Canada reiterated an "outperform" rating and set a target price of $16.00 on January 14th. In total, one analyst has rated the stock as a hold, seven have described it as a buy, and two have declared it a strong buy. According to MarketBeat, the consensus rating for the stock is "Buy", with a consensus target price of $15.13.

Recent Performance of Perspective Therapeutics Stock

On Thursday, CATX opened at $2.61. The stock has seen a low of $2.32 and reached a high of $19.05 over the past year. Its 50-day moving average currently stands at $3.21, while the 200-day moving average is at $7.76.

Investor Activity Surrounding Perspective Therapeutics

In recent weeks, several institutional investors and hedge funds have modified their holdings in CATX. For example, US Bancorp DE increased its position by 142.7% during the third quarter and now holds 6,576 shares valued at approximately $88,000 after acquiring an additional 3,866 shares. Y Intercept Hong Kong Ltd also entered the market, purchasing a new stake worth about $33,000 in the fourth quarter. Intech Investment Management LLC and Aigen Investment Management LP similarly added new positions worth around $137,000 and $34,000, respectively. Notably, National Bank of Canada FI dramatically increased its stake by 549,900.0% in the fourth quarter, owning 11,000 shares valued at about $35,000 after acquiring nearly 11,000 additional shares. Currently, hedge funds and institutional investors own approximately 54.66% of Perspective Therapeutics stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc. is engaged in developing precision-targeted alpha therapies for oncology, specifically aiming to treat cancer patients with various tumor types, including metastatic disease. The company is working on developing its initial program candidates, such as VMT-a-NET, which is in Phase 1/2a clinical trials for patients with unresectable or metastatic tumors expressing somatostatin receptor type 2 (SSTR2) that have not yet received peptide-targeted radiopharmaceutical therapies. Another candidate, VMT01, is currently in Phase 1/2a trials for patients suffering from progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

stock, upgrade, therapy